Wednesday, August 16, 2023
CytoMed Therapeutics has announced its recent collaboration with Hangzhou CNK Therapeutics, marked by the signing of a Memorandum of Understanding (MOU).
This collaboration is aimed at bolstering the in vivo longevity of allogeneic CAR γδ T cells. Notably, this MOU represents the first of multiple cooperative endeavours in North Asia.
With this agreement, CytoMed gains access to CNK's PiggyBac technology, a non-viral gene editing method, enabling the permanent integration of the Chimeric Antigen Receptor (CAR) gene into its gamma delta (γδ) T cells.
The MOU comes with a one-year duration, subject to renewal, and contingent upon a definitive agreement and customary closing conditions. Additionally, the potential for a joint venture to conduct clinical trials in China remains on the horizon.
These strategic collaborations significantly enhance CytoMed's technological prowess, propelling closer to the aspiration of advancing cost-effective, "off-the-shelf" allogeneic cellular immunotherapies to address a wide range of cancer types.
